Imagine a breakthrough in cancer treatment where the body's own immune system gets a powerful boost from radiation therapy, potentially revolutionizing how we tackle stubborn lymphomas—but with a twist that challenges everything we thought we knew about T-cell behavior. Exciting, right? Let's dive into this game-changing study and uncover why T-cell dysregulation might be the key to unlocking better outcomes for patients with B-cell lymphomas.
A groundbreaking phase 1 clinical trial has shown that integrating radiotherapy with immunotherapy not only boosts response rates in B-cell lymphomas but also keeps side effects well under control. Known as the RaDD trial (NCT03610061), this study highlights how radiotherapy paired with immunotherapy led to improved outcomes, all while drawing insights from the intricate world of T-cell function in these patients. For beginners, think of T-cells as the frontline soldiers of your immune system—they're supposed to attack cancer cells, but in some cases, they get thrown off balance, or "dysregulated," which can make treatments less effective. This trial suggests that by tweaking radiation doses and combining them with certain drugs, we can recalibrate those T-cells for better results.
Delving into the numbers, the objective response rate (ORR)—that's the percentage of patients whose tumors shrank or disappeared—was 60% among those with follicular lymphoma (FL, a type of slow-growing lymphoma), based on 3 out of 5 patients responding. For diffuse large B-cell lymphoma (DLBCL, a more aggressive form), it was 14%, with 4 out of 27 patients seeing benefits. Across the board, out of 32 evaluable patients, the overall ORR stood at 22%. This might sound modest at first glance, but in the context of relapsed or refractory cancers—those that haven't responded to previous treatments—it's a promising sign. But here's where it gets controversial: Could these varying response rates mean we're overlooking personalized factors, or is it a hint that not all lymphomas respond equally to this combo?
The trial focused on testing the safety of ramping up radiotherapy doses and the areas treated, alongside the immunotherapy drug durvalumab (commonly known as Imfinzi), in 34 patients battling relapsed or refractory DLBCL or FL. The participants were a diverse group, with a median age of 74 (ranging from 28 to 87), and most (29 out of 34) had DLBCL, while 5 had FL. They underwent a median of 2 cycles of durvalumab (with ranges from 1 to 32 cycles), and the median follow-up period was 7.1 months (spanning from about 0.17 to 60 months). To clarify for those new to this, a "cycle" here means a round of treatment, and durvalumab works by blocking a protein called PD-L1 that cancers use to hide from immune attacks.
When it came to how long responses lasted, the median duration of response (DOR) was 3.3 months (with a 95% confidence interval of 2 to 16 months), and impressively, half of the responders (4 out of 8) maintained their benefits for over 12 months. This suggests the treatment isn't just a short-term fix but could offer lasting relief for some. The study's authors, led by Hawkes et al., pointed out that the safety demonstrated in combining radiotherapy with PD-L1 inhibition opens doors for broader applications. They envision this approach extending to other cancer types and even newer immunotherapies, like bispecific antibodies that connect T-cells directly to tumor cells. For example, imagine these antibodies acting like matchmakers in a crowded party, guiding T-cells straight to the cancer targets.
Moving to the trial's goals, the main aim was to find the best radiotherapy dose to pair with durvalumab for phase 2 testing. Secondary goals included tracking side effects (adverse events, or AEs), overall response rates, how long patients lived without disease progression (progression-free survival, or PFS), overall survival (OS), and the highest tolerable radiotherapy dose. Every patient experienced at least one AE, which is common in cancer trials—think of them as the body's reactions to intense treatments. Serious issues (grade 3 or higher) hit 38% of the participants (13 out of 34), but importantly, no dose-limiting toxicities cropped up, meaning the combination was generally well-tolerated. There was one unfortunate death from sepsis, unrelated to the treatments, and while 8 patients had serious AEs, only 3 were tied to the therapy. Common side effects included drops in neutrophil and platelet counts (key blood cells for fighting infections and clotting), anemia (low red blood cells), nausea and vomiting, and diarrhea. Due to an early, unrelated severe event, 2 DLBCL patients couldn't be fully assessed.
And this is the part most people miss: The trial's authors believe their targeted radiotherapy strategy—focusing only on involved lymph nodes and prioritizing symptomatic or dominant disease sites—could speed up responses compared to broader, regional approaches. By avoiding areas prone to extra toxicity (based on durvalumab's known safety profile), they aimed to cut down on the long wait times typical with PD-L1 inhibitors alone. This focal method treats just the problematic spots, potentially reducing overall strain on the body while still sparking immune reactions. It's a shift from the usual "regional" radiotherapy, which covers larger areas, and could inspire future studies to test if smaller, smarter doses lead to bigger wins.
Now, let's explore the biomarker analysis, where the trial really shines a light on the biology behind the responses. Through a comprehensive program analyzing tissues, blood, and even imaging, researchers found a clear link between T-cell traits and how well treatments worked. For instance, in baseline tumor biopsies (samples taken before treatment), a "T-cell-inflamed" environment—meaning lots of active T-cells ready to fight—was crucial for success. Responders showed much higher T-cell infiltration and markers of killer T-cells (like CD8A) compared to non-responders. Their T-cell activation scores were notably elevated (with a p-value of 0.0013, indicating strong statistical significance). To break this down for newcomers: p-values tell us how likely the results are due to chance; lower than 0.05 usually means they're meaningful.
Further, the balance between T-cell activity and immune-suppressing elements (like PD-L1 expression and M2 macrophages, which are types of cells that dampen immune responses) mattered a lot. Patients who progressed had a worse ratio, favoring suppression (p=0.0051), pointing to how an overactive suppression mechanism can spell trouble. Gene expression of TCF7—a factor linked to "stem-like" T-cells that can be refreshed by therapies—was higher in responders (p=0.0160). Interestingly, baseline PD-L1 gene levels didn't predict outcomes, but a drop in PD-L1 RNA during progression hinted at resistance through down-regulation. This could mean cancers evolve to hide better over time, sparking debates on timing booster treatments.
Shifting to who could join the trial, inclusion criteria were strict but aimed at those with the most need: histologically confirmed CD20-positive relapsed/refractory DLBCL (either newly diagnosed or transformed from slower lymphomas), at least one prior therapy including a CD20-targeted antibody like rituximab (Rituxan), no curative options per the doctor's judgment, and an ECOG performance score of 0 or 1 (indicating they're relatively active and not bedridden). Exclusions kept out those with T-cell or Hodgkin lymphomas, prior treatments targeting T-cell proteins like PD-1 or CTLA-4, or active autoimmune diseases that could flare up with immune-boosting drugs. These rules ensure safety and focus on the right patient group, but they also raise questions about accessibility—could broader criteria include more diverse populations and yield different results?
To wrap up the RaDD trial details: This investigator-led, multicenter phase 1b study used a standard 3+3 design to gradually increase radiotherapy doses and treatment areas. Everyone got at least 5 radiation fractions across 1 to 3 sites, with total doses ranging from 2.5 Gy to 30 Gy in 6 cohorts. Durvalumab was administered at 1500 mg intravenously starting on day 2 of radiotherapy, then every 28 days until progression or intolerable side effects. Planning involved CT-guided imaging to target gross tumor volumes precisely. Cohorts 1-5 escalated doses from 2.5 Gy over 5 fractions to 20 Gy over 5 (a common palliative level with high response rates), while cohort 6 tested 30 Gy over 10 to mitigate risks like tumor lysis syndrome in bulky diseases.
REFERENCES
Hawkes E, Palmer J, Khor R, et al. T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial. Blood Adv (2025) 9 (20): 5263–5273. doi.org/10.1182/bloodadvances.2025016505
A trial of radiotherapy and durvalumab in DLBCL and FL (RaDD). ClinicalTrials.gov. Updated April 12, 2024. Accessed November 4, 2025. https://clinicaltrials.gov/study/NCT03610061
Newsletter
Keep yourself informed on the latest data that's transforming community cancer care—sign up today!
What do you think? Does this trial's focus on T-cell dysregulation challenge traditional radiotherapy approaches in your view, or should we push for even more aggressive combinations? Is the potential for broader applications exciting or ethically fraught? Share your thoughts in the comments—let's discuss the future of lymphoma treatment!
